Gene · 3003
NIH grants2,103
NIH grants whose papers are about the gene, through NIH's grant-paper links.
821 to 840 of 2,103
Download this page as JSON| Grant | Title | GZMK papers | Newest fiscal year |
|---|---|---|---|
| RF1NS122174 | Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement | 2 | 2023 |
| RM1HG007735 | Center for Personal Dynamic Regulomes | 2 | 2023 |
| T32AI007334 | Molecular and Cellular Immunology | 2 | 2023 |
| T32GM087237 | Graduate Training in Computational and Systems Biology | 2 | 2023 |
| U19AI142784 | Autophagy Modulators as Novel Broad-Spectrum Anti-Infective Agents | 2 | 2023 |
| U54DK104310 | Cellular and molecular mediators of fibrosis in the development of urinary tract dysfunction | 2 | 2023 |
| UL1TR001414 | Institute for Clinical and Translational Science | 2 | 2023 |
| DP5OD028171 | Dissecting the influence of DNA damage response and homologous recombination deficiencies on tumor immunogenicity | 1 | 2023 |
| F30CA246920 | Reprogramming tumor-reactive CD8 T cells by targeting the IL-21-BATF pathway to treat melanoma | 1 | 2023 |
| F31AI164869 | Contact-dependent determinants of human natural killer cell development | 1 | 2023 |
| F31CA264849 | Polyamines drive glioblastoma progression | 1 | 2023 |
| F31CA271778 | Towards a spatial view of Ras signaling and immune cell function in NF-1 mutant glioblastoma | 1 | 2023 |
| F31HL156433 | Inferring Gene Regulatory Networks Governing Definitive Endoderm Differentiation from Single Cell RNA Velocity Measurements | 1 | 2023 |
| F32AI157296 | Investigating the cellular responses to influenza virus infection and the origins of first exposure immune imprinting | 1 | 2023 |
| F32HL156452 | Mesenchymal inflammatory signaling in regulation of the immune response and tissue dysfunction during lipopolysaccharide-induced acute lung injury | 1 | 2023 |
| F99CA274688 | Chromatin remodeling in CD8+ T cells and harnessing stromal-immune interactions for effective antitumor immunity | 1 | 2023 |
| I01BX002061 | HCV and co-morbid alcohol use disorders: a translational investigation of antiviral therapy outcomes on CNS function | 1 | 2023 |
| K00CA223043 | Defining the barriers to immune surveillance in solid tumors | 1 | 2023 |
| K08AI141767 | Comparative Animal Models of Viral Hepatitis | 1 | 2023 |
| K08CA231454 | Finding Synergy with Radiation Therapy and Immunotherapy for Patients with Lung Cancer | 1 | 2023 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3003/grants?page=42